Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegcetacoplan in TA-TMA After HSCT
2023-510443-37-00Phase 2Completed
- Sponsor
- Sobi
- Start
- May 2024
- Modality
- PEGylated Peptides → Modified Peptides → Peptides, Recombinant Proteins and Enzymes
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of pegcetacoplan in transplant-associated thrombotic microangiopathy (TA-TMA), sponsored by Sobi. Primary endpoint: Pegcetacoplan pharmacokinetics. Started May 2024; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
transplant-associated thrombotic microangiopathy (TA-TMA)
Beyond the preview
Go deeper on 2023-510443-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510443-37-00.